Bristol-Myers Squibb presents phase II data for pegbelfermin in non-alcoholic steatohepatitis Jan. 11, 2019
Protagonist Therapeutics initiates phase II study of PTG-300 in patients with beta-thalassemia Jan. 11, 2019
Phase III JEWEL study of lurasidone meets primary endpoint in patients with schizophrenia Jan. 11, 2019
RSS